Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
References |
1: Zhao H, Li Y, Hou S, Dai Y, Lin C, Xu S. Incidental detection of primary hepatocellular carcinoma on 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography imaging in a patient with prostate cancer: A case report. Medicine (Baltimore). 2020 Oct 9;99(41):e22486. doi: 10.1097/MD.0000000000022486. PMID: 33031282. 2: Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, Vogel WV, Nagarajah J, Janssen M, Isebaert S, Maes F, Mai C, Oyen R, Joniau S, Kunze-Busch M, Goffin K, Haustermans K. Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Oct 6. doi: 10.1007/s00259-020-05059-4. Epub ahead of print. PMID: 33025093. 3: Privé BM, Isra?l B, Schilham MGM, Muselaers CHJ, Zámecnik P, Mulders PFA, Witjes JA, Sedelaar M, Mehra N, Verzijlbergen F, Janssen MJR, Gotthardt M, Barentsz JO, van Oort IM, Nagarajah J. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2020 Sep 30. doi: 10.1038/s41391-020-00292-2. Epub ahead of print. PMID: 32999466. 4: Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello F. Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2020 Sep 16:101097JU0000000000001369. doi: 10.1097/JU.0000000000001369. Epub ahead of print. PMID: 32935652. 5: Cardinale J, Roscher M, Sch?fer M, Geerlings M, Bene?ová M, Bauder-Wüst U, Remde Y, Eder M, Nováková Z, Motlová L, Barinka C, Giesel FL, Kopka K. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido- Type PSMA Inhibitors. J Med Chem. 2020 Oct 8;63(19):10897-10907. doi: 10.1021/acs.jmedchem.9b01479. Epub 2020 Sep 22. PMID: 32852205. 6: Sprute K, Kramer V, Koerber S, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber W, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. Diagnostic accuracy of 18F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence. J Nucl Med. 2020 Aug 17:jnumed.120.246363. doi: 10.2967/jnumed.120.246363. Epub ahead of print. PMID: 32817141. 7: Foley RW, Redman SL, Graham RN, Loughborough WW, Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol. 2020 Aug 8:S0009-9260(20)30273-7. doi: 10.1016/j.crad.2020.06.031. Epub ahead of print. PMID: 32782128. 8: Naka S, Watabe T, Kurimoto K, Uemura M, Soeda F, Neels OC, Kopka K, Tatsumi M, Kato H, Nonomura N, Shimosegawa E, Cardinale J, Giesel FL, Hatazawa J. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):18. doi: 10.1186/s41181-020-00101-0. PMID: 32728815; PMCID: PMC7391460. 9: Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta- Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, L?yttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Sepp?nen M, Bostr?m PJ. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2020 Jul 13:S2588-9311(20)30090-0. doi: 10.1016/j.euo.2020.06.012. Epub ahead of print. PMID: 32675047. 10: Ar?ay A, Eiber M, Langbein T. Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET. Clin Nucl Med. 2020 Jul;45(7):561-562. doi: 10.1097/RLU.0000000000003081. PMID: 32433166. 11: Tr?g?rdh E, Minarik D, Brolin G, Bitzén U, Olsson B, Oddstig J. Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer. EJNMMI Phys. 2020 May 12;7(1):31. doi: 10.1186/s40658-020-00298-8. PMID: 32399664; PMCID: PMC7218038. 12: Marafi F, Sasikumar A, Alfeeli M, Thuruthel S. 18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer. Clin Nucl Med. 2020 Jun;45(6):e276-e278. doi: 10.1097/RLU.0000000000003013. PMID: 32332302. 13: Ioppolo JA, Nezich RA, Richardson KL, Morandeau L, Leedman PJ, Price RI. Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga- PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Appl Radiat Isot. 2020 Jul;161:109164. doi: 10.1016/j.apradiso.2020.109164. Epub 2020 Apr 2. PMID: 32321698. 14: Haemels M, Jentjens S, Cleeren F, Sciot R, Lambert J, Van Laere K, Goffin K. All that glitters is not prostate cancer: incidental finding of PSMA-avid meningioma. Hell J Nucl Med. 2020 Jan-Apr;23(1):79-80. doi: 10.1967/s002449912007. Epub 2020 Mar 31. PMID: 32222733. 15: Marafi F, Sasikumar A, Al-Terki A, Alfeeli M. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma. Clin Nucl Med. 2020 May;45(5):377-378. doi: 10.1097/RLU.0000000000003002. PMID: 32209880. 16: Mittlmeier LM, Unterrainer M, Todica A, Clevert DA, Cyran CC, Schmoeckel E, Rodler S, Bartenstein P, Stief CG, Ilhan H, Staehler M. Advanced Molecular Imaging in Histologically Verified Metanephric Adenoma. Urology. 2020 Jun;140:e10-e11. doi: 10.1016/j.urology.2020.02.025. Epub 2020 Apr 5. PMID: 32171695. 17: Kairemo K, Kangasm?ki A, Joensuu T, Seregard S. Eye Symptoms in a Patient With Prostate Cancer. Clin Nucl Med. 2020 May;45(5):370-371. doi: 10.1097/RLU.0000000000002982. PMID: 32149800. 18: Witkowska-Patena E, Budzyńska A, Gi?ewska A, Dziuk M, Wal?cka-Mazur A. Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT. Ann Nucl Med. 2020 Mar;34(3):192-199. doi: 10.1007/s12149-019-01433-x. Epub 2020 Jan 4. PMID: 31902120; PMCID: PMC7033087. 19: Hartrampf PE, Seitz AK, Krebs M, Buck AK, Lapa C. False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):2044-2046. doi: 10.1007/s00259-019-04645-5. Epub 2019 Dec 27. PMID: 31879815. 20: Tang K, Wang Z, Lin J, Zheng X. Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT. Clin Nucl Med. 2020 Mar;45(3):223-224. doi: 10.1097/RLU.0000000000002873. PMID: 31876816.
|
---|
Molecular Formula |
C49H55FN8O16
|
---|---|
Molecular Weight |
1031.017
|
Exact Mass |
1030.37
|
Elemental Analysis |
C, 57.08; H, 5.38; F, 1.84; N, 10.87; O, 24.83
|
CAS # |
2093321-19-6
|
Appearance |
Solid powder
|
SMILES |
O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC([C@@H](NC(C1=CC=C(CNC([C@@H](NC([C@@H](NC(C2=CN=C(F)C=C2)=O)CCC(O)=O)=O)CCC(O)=O)=O)C=C1)=O)CC3=CC=C4C=CC=CC4=C3)=O)=O
|
InChi Key |
RFFFFGRYVZESLB-LTLCPEALSA-N
|
InChi Code |
InChI=1S/C49H55FN8O16/c50-38-18-14-32(26-52-38)43(66)54-34(16-20-40(61)62)46(69)55-33(15-19-39(59)60)44(67)53-25-27-8-12-30(13-9-27)42(65)56-37(24-28-10-11-29-5-1-2-6-31(29)23-28)45(68)51-22-4-3-7-35(47(70)71)57-49(74)58-36(48(72)73)17-21-41(63)64/h1-2,5-6,8-14,18,23,26,33-37H,3-4,7,15-17,19-22,24-25H2,(H,51,68)(H,53,67)(H,54,66)(H,55,69)(H,56,65)(H,59,60)(H,61,62)(H,63,64)(H,70,71)(H,72,73)(H2,57,58,74)/t33-,34-,35-,36-,37-/m0/s1
|
Chemical Name |
(((S)-1-carboxy-5-((S)-2-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)butanamido)methyl)benzamido)-3-(naphthalen-2-yl)propanamido)pentyl)carbamoyl)-L-glutamic acid
|
Synonyms |
PSMA-1007; PSMA1007; PSMA 1007;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9699 mL | 4.8496 mL | 9.6991 mL | |
5 mM | 0.1940 mL | 0.9699 mL | 1.9398 mL | |
10 mM | 0.0970 mL | 0.4850 mL | 0.9699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.